Benjamin J. Tuck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Benjamin J. Tuck has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- William A. McEwan
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
3 shared publications Claire Knox
MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
2 shared publications- Lauren V. C. Miller
UK Dementia Research Institute at University of Cambridge, Cambridge United Kingdom
2 shared publications Marina Vaysburd
MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
2 shared publications- Taxiarchis Katsinelos
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
2 shared publications - Aamir Mukadam
UK Dementia Research Institute at University of Cambridge, Cambridge United Kingdom
1 shared publication
Latest Publications
- Open Access
- 23 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6651) , 1258-1265
Perforin-2 is a pore-forming effector of endocytic escape in cross-presenting dendritic cells
During initiation of antiviral and antitumor T cell–mediated immune responses, dendritic cells (DCs) cross-present exogenous antigens on major histocompatibility complex (MHC) class I molecules. Cross-presentation relies on the unusual “leakiness” of endocytic compartments in DCs, whereby internalized proteins escape into the cytosol for proteasome-mediated generation of MHC I–binding peptides. Given that type 1 conventional DCs excel at cross-presentation, we searched for cell type–specific effectors of endocytic escape. We devised an assay suitable for genetic screening and identified a pore-forming protein, perforin-2 ( Mpeg1 ), as a dedicated effector exclusive to cross-presenting cells. Perforin-2 was recruited to antigen-containing compartments, where it underwent maturation, releasing its pore-forming domain. Mpeg1 −/− mice failed to efficiently prime CD8 + T cells to cell-associated antigens, revealing an important role for perforin-2 in cytosolic entry of antigens during cross-presentation.
- 23 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6651) , 1258-1265
Open AccessPerforin-2 is a pore-forming effector of endocytic escape in cross-presenting dendritic cells
During initiation of antiviral and antitumor T cell–mediated immune responses, dendritic cells (DCs) cross-present exogenous antigens on major histocompatibility complex (MHC) class I molecules. Cross-presentation relies on the unusual “leakiness” of endocytic compartments in DCs, whereby internalized proteins escape into the cytosol for proteasome-mediated generation of MHC I–binding peptides. Given that type 1 conventional DCs excel at cross-presentation, we searched for cell type–specific effectors of endocytic escape. We devised an assay suitable for genetic screening and identified a pore-forming protein, perforin-2 ( Mpeg1 ), as a dedicated effector exclusive to cross-presenting cells. Perforin-2 was recruited to antigen-containing compartments, where it underwent maturation, releasing its pore-forming domain. Mpeg1 −/− mice failed to efficiently prime CD8 + T cells to cell-associated antigens, revealing an important role for perforin-2 in cytosolic entry of antigens during cross-presentation.
- Open Access
- 31 March 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 379 (6639) , 1336-1341
Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models
Aggregates of the protein tau are proposed to drive pathogenesis in neurodegenerative diseases. Tau can be targeted by using passively transferred antibodies (Abs), but the mechanisms of Ab protection are incompletely understood. In this work, we used a variety of cell and animal model systems and showed that the cytosolic Ab receptor and E3 ligase TRIM21 (T21) could play a role in Ab protection against tau pathology. Tau-Ab complexes were internalized to the cytosol of neurons, which enabled T21 engagement and protection against seeded aggregation. Ab-mediated protection against tau pathology was lost in mice that lacked T21. Thus, the cytosolic compartment provides a site of immunotherapeutic protection, which may help in the design of Ab-based therapies in neurodegenerative disease.
- 31 March 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 379 (6639) , 1336-1341
Open AccessCytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models
Aggregates of the protein tau are proposed to drive pathogenesis in neurodegenerative diseases. Tau can be targeted by using passively transferred antibodies (Abs), but the mechanisms of Ab protection are incompletely understood. In this work, we used a variety of cell and animal model systems and showed that the cytosolic Ab receptor and E3 ligase TRIM21 (T21) could play a role in Ab protection against tau pathology. Tau-Ab complexes were internalized to the cytosol of neurons, which enabled T21 engagement and protection against seeded aggregation. Ab-mediated protection against tau pathology was lost in mice that lacked T21. Thus, the cytosolic compartment provides a site of immunotherapeutic protection, which may help in the design of Ab-based therapies in neurodegenerative disease.
- Open Access
Tau assemblies enter the cytosol in a cholesterol sensitive process essential to seeded aggregation
Accumulating evidence supports a prion-like mechanism in the spread of assembled tau in neurodegenerative diseases. Prion-like spread is proposed to require the transit of tau assemblies to the interior of neurons in order to seed aggregation of native, cytosolic tau. This process is poorly understood and remains largely hypothetical. Here, we develop sensitive techniques to quantify the cytosolic entry of tau in real-time. We find that tau does not promote its own entry but, rather, is wholly dependent on cellular machinery. We find that entry to the widely used reporter cell line HEK293 requires clathrin whereas entry to neurons does not. Cholesterol depletion or knockdown of cholesterol transport protein Niemann-Pick type C1 in neurons renders cells highly vulnerable to cytosolic entry and seeded aggregation. Our findings establish entry as the rate-limiting step in seeded aggregation and demonstrate that dysregulated cholesterol, a feature of several neurodegenerative diseases, potentiates tau aggregation. Graphical
Open AccessTau assemblies enter the cytosol in a cholesterol sensitive process essential to seeded aggregation
Accumulating evidence supports a prion-like mechanism in the spread of assembled tau in neurodegenerative diseases. Prion-like spread is proposed to require the transit of tau assemblies to the interior of neurons in order to seed aggregation of native, cytosolic tau. This process is poorly understood and remains largely hypothetical. Here, we develop sensitive techniques to quantify the cytosolic entry of tau in real-time. We find that tau does not promote its own entry but, rather, is wholly dependent on cellular machinery. We find that entry to the widely used reporter cell line HEK293 requires clathrin whereas entry to neurons does not. Cholesterol depletion or knockdown of cholesterol transport protein Niemann-Pick type C1 in neurons renders cells highly vulnerable to cytosolic entry and seeded aggregation. Our findings establish entry as the rate-limiting step in seeded aggregation and demonstrate that dysregulated cholesterol, a feature of several neurodegenerative diseases, potentiates tau aggregation. Graphical